79.89 +0.33 (0.41%)
After hours: 7:06PM EDT
|Bid||79.60 x 800|
|Ask||79.90 x 900|
|Day's Range||79.13 - 80.46|
|52 Week Range||65.25 - 92.64|
|Beta (5Y Monthly)||0.51|
|PE Ratio (TTM)||20.17|
|Earnings Date||Jul 31, 2020|
|Forward Dividend & Yield||2.44 (3.02%)|
|Ex-Dividend Date||Jun 12, 2020|
|1y Target Est||93.94|
DOW UPDATE In spite of negative returns for shares of Pfizer and Cisco, the Dow Jones Industrial Average is nearly flat Monday morning. Shares of Pfizer (PFE) and Cisco (CSCO) account for -13% of the index's intraday losses, as the Dow (DJIA) was most recently trading 2 points lower (0.
(Bloomberg) -- The year’s biggest meeting of cancer researchers was subjected to a coronavirus overhaul this year, but even in scaled-back form it forced investors to recalibrate their expectations for some closely watched medicines.The American Society of Clinical Oncology meeting is the field’s most important gathering each spring, providing a stage for major pharmaceutical companies to unveil major findings and tout promising treatments. It’s also an annual opportunity for all kinds of researchers, doctors, executives and investors to rub elbows.With Covid-19 making travel uncomfortable and splashy conferences impossible this year, the summit was mostly a virtual affair. Still, it delivered many of the kinds of important victories and stinging setbacks it often does. And the meeting showed that even as the drug industry races to identify virus treatments and vaccines, cancer remains perhaps its most important business overall.“When the coronavirus wanes and we have a vaccine, and this infectious disease is brought under control, we will still have cancer and the need for new treatments,” said Richard Schilsky, ASCO’s chief medical officer, in an interview. “We have millions of patients around the world who need new and improved treatments for cancer.”Among the most noteworthy winners was U.K. pharmaceutical giant AstraZeneca Plc, which reported that its blockbuster Tagrisso reduced the risk of dying from lung cancer or relapse by four-fifths over three years. The drug is already AstraZeneca’s biggest product, bringing in $982 million in sales in the first quarter alone.Some smaller drug companies also logged what looked like significant victories: Trillium Therapeutics Inc. said that a second patient taking its experimental lymphoma therapy responded to the treatment. Shares of Trillium, which has a market value of about $560 million, surged more than 17% on FridayAnd as ASCO played out, other big cancer-research news also roiled drugmaker stocks.Pfizer Inc. shares fell 5.1% in trading before U.S. exchanges opened Monday after the U.S. drug bellwether said a late-stage study of its treatment for metastatic breast cancer, Ibrance, was unlikely to show a statistically significant improvement in invasive disease-free survival for patients with early breast cancer.Though the Covid-19 pandemic has been the defining story of the health-care business this year, the ASCO meeting was a reminder that most of the world’s pharmaceutical companies remain keenly focused on finding new cancer treatments to generate profits. And that focus has paid off for patients: The U.S. death rate from cancer has been falling at a record pace, thanks largely to big advances in treating lung tumors.Data presented at the meeting showed progress in combating the second leading cause of death worldwide, Schilsky said. Researchers found medicines used for patients with advanced disease can have an even bigger benefit for those with recently diagnosed tumors, while medicines are emerging that are effective against a wide range of tumors that are driven by specific gene mutations.Deals Getting DoneLarge drugmakers have remained on the prowl for promising cancer therapies that they can acquire through mergers or other transactions. Even Gilead Sciences Inc., which has been in the headlines because of its potential coronavirus treatment remdesivir, has been getting cancer-focused deals done against the backdrop of the pandemic.Last week, Gilead agreed to work on immunotherapy drugs with biotech Arcus Biosciences Inc. And earlier this year it agreed to buy cancer-drug maker Forty Seven for $4.9 billion. Gilead has been pressured by investors to find new drugs that can take the place of some of its aging blockbusters. It made another big bet on cancer when it bought Kite Pharma and its drug Yescarta, though sales of the highly priced genetic therapy have so far failed to live up to expectations.At ASCO, Gilead presented encouraging new data on magrolimab, an immunology drug that was developed by Forty Seven, a sign that the company’s wager could pay off. Gilead’s management is successfully building a pipeline of potential new therapies, Jefferies & Co. analyst Michael Yee said in a note sent to clients.Gilead shares dropped 1.5% early Monday. They now have gained about 20% so far this year, in part because of excitement over remdesivir.Breakthroughs at ASCO could make smaller companies enticing to Gilead and to other giants looking to add to their rosters of experimental therapies. Adaptimmune Therapeutics Plc’s U.S.-traded shares more than doubled in value after the company presented early studies for therapies that could treat a number of cancers, including lung and head and neck tumors.Allogene Therapeutics Inc., which is developing a CAR-T therapy similar to Yescarta, gained 3.5% Friday after it said its treatment benefited 63% of patients with blood cancer in an early-stage trial. Allogene’s founders ran Kite Pharma before selling it to Gilead for $11 billion in 2017.Dueling GiantsLike Gilead, Bristol-Myers Squibb Co. has also sought to refashion itself into a cancer-fighting juggernaut, mostly notably with its $74 billion takeover of Celgene Corp. last year. Even before that transaction, the company was locked in a battle with rival Merck & Co. for supremacy in the market for lung-cancer immunotherapies.Merck’s Keytruda and Bristol-Myers’s Opdivo are blockbusters for each company, and the drugmakers have raced to expand their use in a range of tumor types. But at ASCO, a study of Opdivo in combination with another Bristol-Myers drug, Yervoy, supported what JPMorgan Chase & Co. analyst Chris Schott said in a note was a “niche role” in treating certain lung-cancer patients -- not one that will upset Keytruda’s dominance.Bristol-Myers shares declined 0.2% on Friday, while Merck advanced 2.1%. Both were little changed before U.S. markets opened Monday.Last year, Opdivo generated $7.2 billion in revenue for Bristol-Myers, while Yervoy brought in $1.5 billion. Together, the two drugs accounted for roughly a third of the company’s sales. Meanwhile, Keytruda generated $11 billion for Merck, about 24% of its sales.Another challenge to Keytruda may come from Switzerland’s cancer titan Roche Holding AG. The drugmaker presented data at ASCO showing that combining the experimental tiragolumab with one of its proven medicines, Tecentriq, worked better than prescribing Tecentriq alone in patients with metastatic non-small-cell lung cancer. The phase 2 data suggests it “could potentially compete with Merck’s Keytruda in a segment of lung-cancer patients,” wrote Cinney Zhang of Bloomberg Intelligence.Some Chinese drugmakers also showed promising findings in liver cancer. A combination from Innovent Biologics Inc. showed initial efficacy comparable to Roche in hepatocellular carcinoma, for which China accounts for almost than half of new cases. Innovent shares surged 10% in Hong Kong trading Monday.(Updates with share moves for Pfizer, Gilead and Innovent in eighth, 14th and last paragraphs)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Antipodes Partners recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Antipodes Global Fund posted a return of -5.3% for the quarter, outperforming its benchmark, the MSCI AC World Net Index which returned -9.7% in the same quarter. You should check out Antipodes Partners top 5 stock picks […]
Given strong dividend growth and big money signals, these stocks could be worth a spot in a yield-oriented portfolio.
The biotech company has dosed the first volunteers in the next phase of testing for its vaccine against the Covid-19 virus.
LYNPARZA Receives Positive Opinion from EU CHMP for First-Line Maintenance of Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer
The company produced expectation-beating results. The acquisition of Celgene has gone very well, but shares trade with a multiple of less than 10 times earnings Continue reading...
Biotech stocks could not sustain the uptrend in the holiday-shortened week, even as traders digested COVID-19-related news flow, clinical readouts, ASCO presentations and a few FDA approvals.Arca Biopharma Inc (NASDAQ: ABIO) was the best performing biotech stock of the week, as it rallied in reaction to an announcement from the company regarding testing of its pipeline asset for COVID-19-associated coagulopathy.The week also saw Merck & Co., Inc. (NYSE: MRK) taking a giant leap of faith into the COVID fray after remaining non-committal thus long.Here are the key catalysts for the unfolding week.Conferences Jefferies Virtual Healthcare Conference: June 2-4 European Academy of Allergy and Clinical Immunology, or EAACI, Digital Conference 2020: June 6-8PDUFA Dates The FDA is set to rule on Menlo Therapeutics Inc's (NASDAQ: MNLO) FMX103 - 1.5% minocycline foam -, which came into its stable via its Foamix acquisition, as a treatment option for moderate-to-severe papulopustular rosacea. (Tuesday)Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and AbbVie Inc (NYSE: ABBV) await FDA verdict on the latter's NDA for elagolix, which is being evaluated for treating uterine fibroids. (likely on Thursday)Merck's sNDA for its triple combo antibiotic Recarbrio has a PDUFA date of June 6.See Also: PhaseBio Analyst Says Coronavirus Study Creates Near-Term CatalystClinical Readouts ASCO 2020 Annual Meeting (presentations during the plenary session scheduled for Sunday)View more earnings on IBBAstraZeneca plc (NYSE: AZN) is scheduled to present detailed results from the Phase 3 ADAURA trial of its Tagrisso in early-stage epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent.Merck will present results of a Phase 3 study evaluating Keytruda as a first-line treatment of patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer.EAACI Digital Conference Presentations Celldex Therapeutics, Inc. (NASDAQ: CLDX) will make a late-breaking poster presentation of data from the Phase 1 healthy volunteer study of its KIT inhibitor, CDX-0159.Standalone Releases Replimune Group Inc (NASDAQ: REPL) is scheduled to provide updated Phase 1/2 data from patients with melanoma and non-melanoma skin cancers treated with RP1 combined with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo. (Wednesday)Earnings Protalix Biotherapeutics Inc (NYSE: PLX) (Monday, before the market open)IPO Legend Biotech, a clinical-stage biotech engaged in the discovery and development of novel cell therapies for oncology and other indications, has filed to offer 18.425 million ADSs in an IPO, with each ADS representing two ordinary shares. The company expects the IPO to be priced between $18 and $20. It has applied to list its ADSs on the Nasdaq under the ticker symbol "LEGN."California-based Pliant Therapeutics, Inc. is planning a 6-million share offering to be priced between $14 and $16. The clinical-stage biopharma focused on discovering and developing novel therapies for the treatment of fibrosis has applied to list its shares on the Nasdaq under the ticker symbol "PLRX."IPO Quiet Period Expiry Ayala Pharmaceuticals Inc (NASDAQ: AYLA)See more from Benzinga * The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant * The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer * The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Keytruda reduced the risk of disease progression or death by 40% compared to chemotherapy. Put another way, patients treated with Keytruda lived for 16.5 months without their tumors starting to grow, compared to 8.2 months for patients treated with chemotherapy.
A panel of the European health regulator on Friday recommended approving Johnson & Johnson's two-dose experimental vaccine for Ebola in the European Union. J&J submitted its application to the European Medicines Agency (EMA) in November for its vaccine, which targets an Ebola strain that causes the virus in most people. The company in February said it was developing a coronavirus vaccine program that would utilize the same technologies used to make the experimental Ebola vaccine.
What investor doesn't want to own a solid company with exciting prospects for business growth in the near- and mid-term? Here we explore a few interesting opportunities ranging from a big pharma name to a pre-revenue biotech. If you want a solid stock that allows you to sleep soundly at night, buy Merck (NYSE: MRK).
KEYTRUDA® plus LENVIMA® Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable HCC and ccRCC
Merck’s KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer
DOW UPDATE Shares of Merck and Pfizer are trading higher Thursday afternoon, sending the Dow Jones Industrial Average into positive territory. Shares of Merck (MRK) and Pfizer (PFE) are contributing to the blue-chip gauge's intraday rally, as the Dow (DJIA) is trading 86 points, or 0.
As the fallout from the coronavirus pandemic continues, the search for a vaccine is not slowing down.
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DOW UPDATE The Dow Jones Industrial Average is climbing Thursday morning with shares of Boeing and Merck delivering the strongest returns for the blue-chip average. The Dow (DJIA) is trading 138 points higher (0.
U.S. drugmaker Pfizer Inc has signed a long-term agreement with glass maker Corning Inc to procure vials for storing drugs, the companies said on Thursday. Pfizer said the glass vials will be used for some of its existing sterile injectable medicines and that they were also being assessed for storing a range of new products. Pfizer, like rivals Merck & Co and AstraZeneca , is racing to develop a vaccine for the illness which does not yet have an approved vaccine or treatment.
DOW UPDATE The Dow Jones Industrial Average is up Thursday morning with shares of Boeing and Merck leading the way for the blue-chip average. The Dow (DJIA) was most recently trading 69 points, or 0.3%, higher, as shares of Boeing (BA) and Merck (MRK) are contributing to the index's intraday rally.
Nobody will get preferential access to a potential COVID-19 drug developed by vaccine maker Themis Bioscience, which is being bought by U.S. pharmaceuticals firm Merck & Co Inc, the Austrian firm's chief executive said on Thursday. "Merck has already demonstrated in the past ... that it makes vaccines available to anybody who needs them," Erich Tauber told Reuters on Thursday, adding a potential vaccine would be made available globally. "It is one of the reasons why we have decided to cooperate with Merck."
The three major indexes closed in the green on Tuesday, as investors remained hopeful about coronavirus vaccine and that economies around the globe were recovering from the pandemic-driven lockdown over the past few months.
Merck (MRK) to buy Themis, which is making a COVID-19 vaccine. It is also buying global rights to a private biotech's antiviral candidate, EIDD-2801, which is in early clinical studies to treat COVID-19.
Merck (MRK) CEO Kenneth Frasier has warned that the 12- to 18-month targets being suggested for a Covid-19 vaccine are “very aggressive,” telling the Financial Times, “it is not something I would put out there that I would want to hold Merck to.”“Speed is one factor, but in some ways we don’t really accept the concept of a race … We understand the urgency, but our goal isn’t to be the frontrunner in the early stages — it’s to develop a vaccine that is safe and effective” Frasier told the Financial Times.On Tuesday Merck became the latest drugmaker to join the race for the development of a COVID-19 treatment by announcing the purchase of Austrian vaccine maker Themis Bioscience and the collaboration with non-profit research group IAVI.The vaccine candidate being developed with IAVI will use the recombinant vesicular stomatitis virus (rVSV) technology that is the basis for Merck’s Ebola Zaire virus vaccine, ERVEBO (Ebola Zaire Vaccine, Live), which was the first rVSV vaccine approved for use in humans. Clinical studies are planned to start later this year.In general very large “clinical trials take a long time,” the Merck CEO told CNBC, adding “If you’re going to immunize a lot people, millions if not billions of people, you’re going to have to make sure that you know exactly what that vaccine will do in people and you can ensure the safety of people.”Overall, the stock scores a bullish Strong Buy Street consensus with 8 recent Buy ratings and 2 Hold ratings. The $92.10 average price target suggests 19% upside potential in the shares in the coming 12 months. Shares are currently trading down 15% year-to-date. (See Merck stock analysis on TipRanks).Following Merck’s announcements, Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on the stock with a $100 price target.“As a major player in vaccine development (also the first licensed Ebola vaccine), this move makes sense. MRK was not the first to announce plans to tackle Covid-19 but this is not inconsistent with the company’s historically more measured responses,” Goldstein told investors on May 26.Related News: Novavax Begins Human Testing For Covid-19 Vaccine, Expects Results In July Merck Joins Race For Covid-19 Vaccine; Shares Rise 4.4% In Pre-Market Trading Regeneron To Repurchase $5 Billion Stake From Sanofi More recent articles from Smarter Analyst: * Coty Names Chairman Peter Harf As CEO To Steer Strategic Turnaround; Shares Pop 18% * Abiomed’s Heart Pump Gets FDA Emergency Use Status For Covid-19 Patients * Eli Lilly’s Taltz Injection Gets FDA Nod For Inflammatory Spine Arthritis Treatment * Eli Lilly Starts Dosing Patients In World’s First Covid-19 Antibody Trial
Merck is launching its hunt for a coronavirus treatment with a pill developed by US academics that is designed to force an “error catastrophe” on viruses. The drug completed its first safety trial in about 100 human volunteers in the UK and is set to begin extensive clinical testing in the US and UK early in June. Merck, the giant US drug group, said this week that it would develop the drug in collaboration with Ridgeback Biotherapeutics, a small Florida company that had licensed rights to the drug from its discoverers at Emory University in Atlanta.
Shares of Moderna and Novavax, which have risen on positive vaccine developments, fall sharply in late trading.